Changes

|Yes (ALK-negative IMTs may have a higher likelihood of metastasis)

|Yes (ALK-negative IMTs may have a higher likelihood of metastasis)

|Yes

|Yes

|IMT with ALK genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component <ref name=":10" /><ref name=":6" /><ref name=":2" />

|IMT with ''ALK'' genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component <ref name=":10" /><ref name=":6" /><ref name=":2" />

|-

|-

|t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3)

|t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3)

|No

|No

|Yes

|Yes

|Therapy options for NTRK fusions include Larotrectinib and Entrectinib (clinically approved)

|Therapy options for ''NTRK'' fusions include larotrectinib and entrectinib (clinically approved)

|-

|-

|t(5;12)(q32;q13.3)

|t(5;12)(q32;q13.3)

|NAB2::PDGFRB

|''NAB2''::''PDGFRB''

|der(5)

|der(5)

|>1%<ref name=":8" />

|>1%<ref name=":8" />

|-

|-

|rea(10q11.21)

|rea(10q11.21)

|rea(RET)

|rea(''RET'')

|der(10)

|der(10)

|>1%<ref name=":5" />

|>1%<ref name=":5" />

==References==

==References==

(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />

<references />

<br />

<br />